Teduglutide Viatris is a medicine for treating short bowel syndrome (or short gut) in adults and children aged 4 months and above. Short bowel syndrome is a condition in which nutrients and fluids are not properly absorbed by the gut, usually because a large part of the intestine has been surgically removed. Teduglutide Viatris contains the active substance teduglutide and is a ‘generic medicine’. This means that Teduglutide Viatris contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Teduglutide Viatris is Revestive.
Therapeutic Indication
### Therapeutic indication Teduglutide Viatris is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.
Therapeutic Area (MeSH)
ATC Code
A16AX08
ATC Item
teduglutide
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| teduglutide | N/A | 替度格鲁肽 |
EMA Name
Teduglutide Viatris
Medicine Name
Teduglutide Viatris
Aliases
N/ANo risk management plan link.
